Incyte Corp
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −4.31%.
Did INCY Beat Earnings? Q4 2025 Results
Incyte closed out the fourth quarter of 2025 with a split verdict, posting revenue that cleared expectations by a wide margin while falling short on the bottom line. The biotech generated $1.51 billion in Q4 revenue, topping the $1.35 billion consensus by 12.01% and marking a 27.8% increase year-over-year, though earnings per share of $1.80 missed the $1.91 consensus estimate by 5.76%. A key driver of the revenue beat was $100 million in milestone and contract revenue that had no comparable contribution in the prior-year quarter, alongside continued momentum from Jakafi, which contributed $828.24 million in net product revenue, up 7%, and Opzelura, which added $207.28 million, up 28%. Niktimvo, launched earlier in 2025 for chronic GVHD, contributed $56.04 million in the quarter. Looking ahead, Incyte guided 2026 total net product revenue of $4.77 billion to $4.94 billion, underpinned by an active pipeline that includes fourteen pivotal clinical trials and multiple anticipated regulatory milestones throughout the year.
- Jakafi demand growth of 11% in Q4 across all indications
- Opzelura demand and refill growth in atopic dermatitis and vitiligo, including pediatric AD launch and ex-U.S. vitiligo launch
- Strong Niktimvo uptake following 2025 launch in chronic GVHD
- Monjuvi/Minjuvi growth driven by approval and launch in relapsed/refractory follicular lymphoma
- Zynyz growth driven by approval and launch in squamous cell carcinoma of the anal canal
- $100 million in milestone and contract revenue in Q4 2025
- Contract dispute settlement with Novartis resulted in $242.2 million benefit
“Our fourth quarter and full year 2025 results reflect exceptional core business growth and pipeline progress. During the year, we achieved multiple regulatory approvals and several important clinical milestones, allowing us to advance multiple assets from early- to late-stage development. By the end of the year, we expect to have fourteen pivotal clinical trials underway. Incyte enters 2026 with strong business momentum, an innovative, strategically focused pipeline, and a clear strategy for capital allocation and long-term growth.”
Incyte CEO, on the earnings call
Forward Guidance & Outlook
For fiscal year 2026, Incyte guides total net product revenue of $4,770 to $4,940 million, comprising: Jakafi net product revenue of $3,220 to $3,270 million (including potential Jakafi XR launch if approved); Opzelura net product revenue of $750 to $790 million (including anticipated ex-U.S. launch in moderate AD in late 2026); and Hematology and Oncology net product revenue of $800 to $880 million. Total GAAP R&D and SG&A operating expenses are guided at $3,495 to $3,675 million. The company expects fourteen pivotal clinical trials underway, with multiple regulatory decisions and data readouts anticipated throughout 2026, including Jakafi XR (mid-2026), Opzelura in EU for moderate AD (H2 2026), povorcitinib NDA acceptance (Q1 2026), and registrational programs for INCA033989 in ET and MF.
INCY YoY Financials
INCY Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.